Terms: = Uterine cancer AND PIK3R1, P27986, 5295, ENSG00000145675, p85-ALPHA, GRB1 AND Treatment
11 results:
1. Proteogenomic insights suggest druggable pathways in endometrial carcinoma.
Dou Y; Katsnelson L; Gritsenko MA; Hu Y; Reva B; Hong R; Wang YT; Kolodziejczak I; Lu RJ; Tsai CF; Bu W; Liu W; Guo X; An E; Arend RC; Bavarva J; Chen L; Chu RK; Czekański A; Davoli T; Demicco EG; DeLair D; Devereaux K; Dhanasekaran SM; Dottino P; Dover B; Fillmore TL; Foxall M; Hermann CE; Hiltke T; Hostetter G; Jędryka M; Jewell SD; Johnson I; Kahn AG; Ku AT; Kumar-Sinha C; Kurzawa P; Lazar AJ; Lazcano R; Lei JT; Li Y; Liao Y; Lih TM; Lin TT; Martignetti JA; Masand RP; Matkowski R; McKerrow W; Mesri M; Monroe ME; Moon J; Moore RJ; Nestor MD; Newton C; Omelchenko T; Omenn GS; Payne SH; Petyuk VA; Robles AI; Rodriguez H; Ruggles KV; Rykunov D; Savage SR; Schepmoes AA; Shi T; Shi Z; Tan J; Taylor M; Thiagarajan M; Wang JM; Weitz KK; Wen B; Williams CM; Wu Y; Wyczalkowski MA; Yi X; Zhang X; Zhao R; Mutch D; Chinnaiyan AM; Smith RD; Nesvizhskii AI; Wang P; Wiznerowicz M; Ding L; Mani DR; Zhang H; Anderson ML; Rodland KD; Zhang B; Liu T; Fenyö D;
Cancer Cell; 2023 Sep; 41(9):1586-1605.e15. PubMed ID: 37567170
[TBL] [Abstract] [Full Text] [Related]
2. Towards less invasive molecular diagnostics for endometrial cancer: massively parallel sequencing of endometrial lavage specimens in women attending for an office hysteroscopy.
Chao A; Wu KY; Lin CY; Lee YS; Huang HJ; Tang YH; Weng CH; Chao AS; Chang TC; Lai CH; Wu RC
J Mol Med (Berl); 2022 Sep; 100(9):1331-1339. PubMed ID: 35953603
[TBL] [Abstract] [Full Text] [Related]
3. Distinct Genomic Landscapes in Early-Onset and Late-Onset Endometrial cancer.
Choi J; Holowatyj AN; Du M; Chen Z; Wen W; Schultz N; Lipworth L; Guo X
JCO Precis Oncol; 2022 Feb; 6():e2100401. PubMed ID: 35108035
[TBL] [Abstract] [Full Text] [Related]
4. Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway.
Rubinstein MM; Hyman DM; Caird I; Won H; Soldan K; Seier K; Iasonos A; Tew WP; O'Cearbhaill RE; Grisham RN; Hensley ML; Troso-Sandoval T; Sabbatini P; Guillen J; Selcuklu SD; Zimel C; Torrisi J; Aghajanian C; Makker V
Cancer; 2020 Mar; 126(6):1274-1282. PubMed ID: 31880826
[TBL] [Abstract] [Full Text] [Related]
5. Molecular profiling and molecular classification of endometrioid ovarian carcinomas.
Cybulska P; Paula ADC; Tseng J; Leitao MM; Bashashati A; Huntsman DG; Nazeran TM; Aghajanian C; Abu-Rustum NR; DeLair DF; Shah SP; Weigelt B
Gynecol Oncol; 2019 Sep; 154(3):516-523. PubMed ID: 31340883
[TBL] [Abstract] [Full Text] [Related]
6. Gene Expression Analysis Identifies Novel Targets for Cervical cancer Therapy.
Roszik J; Ring KL; Wani KM; Lazar AJ; Yemelyanova AV; Soliman PT; Frumovitz M; Jazaeri AA
Front Immunol; 2018; 9():2102. PubMed ID: 30283446
[TBL] [Abstract] [Full Text] [Related]
7. Image-guided tandem and cylinder brachytherapy as monotherapy for definitive treatment of inoperable endometrial carcinoma.
Gebhardt B; Gill B; Glaser S; Kim H; Houser C; Kelley J; Sukumvanich P; Edwards R; Comerci J; Olawaiye A; Courtney-Brooks M; Boisen M; Berger J; Beriwal S
Gynecol Oncol; 2017 Nov; 147(2):302-308. PubMed ID: 28923412
[TBL] [Abstract] [Full Text] [Related]
8. PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2
Packer LM; Geng X; Bonazzi VF; Ju RJ; Mahon CE; Cummings MC; Stephenson SA; Pollock PM
Mol Cancer Ther; 2017 Apr; 16(4):637-648. PubMed ID: 28119489
[TBL] [Abstract] [Full Text] [Related]
9. Analysis of differentially expressed genes between endometrial carcinosarcomas and endometrioid endometrial carcinoma by bioinformatics.
Lin H; Zhang M; Yu H; Zhang H; Li Y; Xu J; Chen X; Chen Y
Arch Gynecol Obstet; 2016 May; 293(5):1073-9. PubMed ID: 26374646
[TBL] [Abstract] [Full Text] [Related]
10. Endometrial Carcinomas With Clear Cells: A Study of a Heterogeneous Group of Tumors Including Interobserver Variability, Mutation Analysis, and Immunohistochemistry With HNF-1β.
Han G; Soslow RA; Wethington S; Levine DA; Bogomolniy F; Clement PB; Köbel M; Gilks B; DeLair D
Int J Gynecol Pathol; 2015 Jul; 34(4):323-33. PubMed ID: 25851704
[TBL] [Abstract] [Full Text] [Related]
11. Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma.
Matulonis U; Vergote I; Backes F; Martin LP; McMeekin S; Birrer M; Campana F; Xu Y; Egile C; Ghamande S
Gynecol Oncol; 2015 Feb; 136(2):246-53. PubMed ID: 25528496
[TBL] [Abstract] [Full Text] [Related]
